Antisoma's ASA404 yields positive results in Ph II trial

London, UK-based cancer drug developer Antisoma says that its single-arm Phase II trial of ASA404 in non-small cell lung cancer (all histologies) has produced positive final results. In particular, survival data support the findings from an earlier, randomized study in which addition of ASA404 to standard chemotherapy produced one of the largest increases in median survival ever reported in lung cancer, the firm noted.

Findings from the trial, which tested an 1800mg/m2 dose of ASA404 in combination with chemotherapy, will be presented at the World Lung Cancer Conference, to be held in Seoul, Korea, and will include independently determined tumor response rates and time-to-tumour-progression findings, as well as survival data.

Ursula Ney, Antisoma's chief operating officer, said: "these positive results strongly support our earlier trial findings, which showed that adding ASA404 to chemotherapy improves survival in patients with lung cancer."